Zurich launches CancerCare and Second Opinion Services for group risk customers

Zurich Corporate Risk has introduced Precision CancerCare and Second Medical Opinion services for its Group Risk customers, in partnership with Further Group , a specialist in health service solutions. The offering is available to new policies and customers undergoing rate retests from April 1, 2025.

Cancer remains the leading cause of claims for Zurich Corporate Risk. Through Precision CancerCare™, eligible employees diagnosed with advanced or complex cancers will gain access to genetic testing, expert clinical review, and personalized treatment guidance based on the tumour’s molecular profile. The service also includes genetic counseling for hereditary mutations and assistance with clinical trial navigation.

The Second Medical Opinion service offers independent evaluations of diagnoses and treatment plans by global medical experts. The service is available once per unique diagnosis and covers conditions such as cancer, heart surgery, neurosurgery, and organ transplants. Support extends to spouses, partners, and dependent children up to age 22.

Both services are designed to support patients through serious health challenges by improving treatment accuracy and helping individuals make informed decisions about their care.